←
Amy Lee Lightner, MD1,781 posts
Amy Lee Lightner, MD avatar

Amy Lee Lightner, MD

@AmyLightnerMD

Colorectal surgeon and researcher specializing in IBD #regenerativemedicine #stemcell therapy #colorectalresearch

◷ Joined June 2017▧ 136 Photos and videos
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Jun 12

Earlier this week, Calibr-Skaggs announced two milestones in the clinical advancement of CLF065, its potential best-in-class, long-acting glucagon-like peptide-2 (GLP-2) receptor agonist in development for inflammatory bowel diseases (IBD). Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase 2, 105-patient study in Crohn’s disease. CLF065 is the first long-acting GLP-2 analog to enter Phase 2 trials specifically for IBD, with a pharmacology that supports the potential for once-monthly dosing intervals. “For people with IBD, today’s therapies focus almost entirely on suppressing inflammation, without repairing the damaged intestinal lining that drives the disease," says @AmyLightnerMD, chief medical officer at Calibr-Skaggs and principal investigator of the pouchitis study. "CLF065 is designed to both actively regenerate and repair the gut epithelium, thereby complementing anti-inflammatory agents to change the IBD treatment paradigm.” More: ow.ly/N9ux50Zbc6P

Post attachment
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Jun 10

Current therapies for inflammatory bowel disease (IBD) primarily focus on suppressing inflammation. But what if we could repair one of the underlying drivers of disease itself? Researchers at Calibr-Skaggs are developing CLF065, a potential first-in-class regenerative medicine designed to restore epithelial barrier function—the protective intestinal lining that regulates what passes from the gut into the body. CLF065 is designed with a dual mechanism of action: supporting barrier integrity and stimulating regeneration of the gut lining. A Phase 2 clinical trial has recently launched in chronic pouchitis, a painful inflammatory condition that can develop in some people with IBD following surgery. In addition, an Investigational New Drug (IND) application has been submitted to support a Phase 2 trial in Crohn's disease. Learn how regenerative medicine could help shift the treatment paradigm from managing symptoms to repairing the tissue damage at the root of disease. More: ow.ly/plfR50Zabqq

2:09
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Jun 9

At Scripps Research and Calibr-Skaggs, scientists are developing regenerative medicine therapies designed to help the body repair itself from within. Researchers are exploring new approaches for heart failure, IPF, IBD, age-related macular degeneration and more. More: ow.ly/K8Zz50Z8cPS

2:20
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Apr 29

Biomedical research has produced many of the discoveries that underpin modern medicine, but turning those findings into real treatments—and maintaining the research enterprise behind them—requires new approaches. In last week's free Front Row lecture, Scripps Research President and CEO Peter Schultz described how the institute is building a nonprofit model that brings basic science and translational research together to move promising ideas toward medicines more effectively. He highlighted advances spanning aging, artificial intelligence (AI) and global health while also making the case for a more sustainable way to support innovative science. Watch the full lecture now at ow.ly/qA6Q50YQNMv #ScrippsResearch #Nonprofit #Biomedial #Research #Science #Biotech

Post attachmentPost attachmentPost attachmentPost attachment
Amy Lee Lightner, MD avatar
Amy Lee Lightner, MD@AmyLightnerMD·Apr 10

Amazing to see colleagues recognized for the translational work being done #1 in US in biological science …translation to patient impact is seen every day

In @usnews’ 2026 Best Science Schools rankings, the Skaggs Graduate School (@ScrippsGradPrgm) ranked No. 1 in Biological Sciences and No. 7 in Chemistry, rising from No. 9 in Biological Sciences and reaffirming its strength in chemistry education. More: ow.ly/qRgo50YGIqc

Post attachment
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Mar 3

Scripps Research welcomes healthcare innovator Joe Kiani to its Board of Directors. Kiani brings decades of experience in patient safety and public service, and is the founder of Willow Laboratories and Masimo, known for advancing noninvasive patient monitoring technologies. More: ow.ly/pHut50YomVJ

Post attachment
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Feb 14

Not all matters of the heart are metaphorical, including a damaged one ❤️‍🩹 Scientists across Scripps Research, working with the Calibr-Skaggs Institute for Innovative Medicines, are advancing regenerative medicine approaches that could help injured heart tissue repair itself—moving beyond symptom management toward restoring function. This work, led in part by @MichaelBollong and Peter Schultz, focuses on first-in-class small molecules that activate pathways to stimulate new cardiac muscle growth after injury. These efforts are part of a broader pipeline aimed at repairing tissues of the heart, lungs, gut, and more. The image below shows cardiac damage after myocardial infarction (left) and how a regenerative medicine approach developed at Scripps Research stimulates repair by expanding new cardiac muscle cells (right). The research was featured in @WSJ, highlighting the potential of regenerative approaches to reshape treatment for aging-related diseases. Learn more in the comments below.

Post attachment
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·Feb 15

Two years ago today, San Diego officially declared February 15, 2024, “Scripps Research Day” in recognition of the institute’s 100 years of scientific discovery. The day remains a meaningful milestone in our history and a reminder of how deeply our science has changed lives.

Post attachmentPost attachmentPost attachmentPost attachment
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·28 Oct 2025

Long before a medicine reaches a pharmacy, hospital, or clinic, it begins inside a lab like those at Scripps Research. Here, scientists spend years turning discoveries into new therapies, leading to more than 15 FDA-approved treatments that have helped people worldwide. Learn more: ow.ly/aHZs50XjnU7

1:48
Scripps Research avatar
⟳ Amy Lee Lightner, MD retweeted
Scripps Research@scrippsresearch·15 Sep 2025

📣 We’re just days away from #IBDCuttingEdge2025 —a three-day CME event exploring the future of IBD care: translational science, clinical trials, surgery, and multidisciplinary models led by top experts. Join us: 📅 Sept 19–21, 2025 📍Coronado, CA 🎟️ ow.ly/v6qx50VFLVm

Post attachment
Amy Lee Lightner, MD avatar
Amy Lee Lightner, MD@AmyLightnerMD·9 Sep 2025

Thank you to #scrippsresearch #calibr-skaggs to continuing to push #innovation and #education for #IBD we are fortunate to have a community of scientists here who are committed to finding a cure for our patients

The data is clear: inflammatory bowel diseases like ulcerative colitis and Crohn’s are on the rise worldwide. In this episode, we sit down with Dr. Amy Lightner (@AmyLightnerMD)—VP of Clinical Development at Calibr-Skaggs and colorectal surgeon at Scripps Clinic—to explore what drives these diseases, an upcoming phase 2 clinical trial for a new regenerative medicine, and how she balances life between the operating room and the research lab. 🎧 What’s next for IBD care: Insights from a surgeon-scientist is now streaming on the Science Changing Life podcast. Listen now at: ow.ly/o3IX50WTuyG #IBD #Crohnsdisease #UlcerativeColitis #Coloncancer #ScrippsResearch

0:40